Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment
Key facts
- Where
- Umeå, SwedenSee the site
Where in Sweden
- Norrlands University HositalUmeå, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Umeå University
- Trial code
- NCT07524426
- Record updated
- 9 June 2026
- Original description
The goal of this clinical trial is to improve the quality of life and prolong survival in bladder cancer patients unfit for curative treatment. The trial will compare the survival and symptoms of patients randomized to either local radiotherapy in addition to standard of care or standard of care alone.Read full original descriptionShow less
Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment; a Prospective Randomized Phase III Trial.
The goal of this clinical trial is to improve the quality of life and prolong survival in bladder cancer patients unfit for curative treatment. The trial will compare the survival and symptoms of patients randomized to either local radiotherapy in addition to standard of care or standard of care alone.
Using modern radiotherapy techniques, including hypofractionation and image-guided treatment adaptation, the aim is to deliver a well-tolerated, time-efficient, and effective treatment strategy for these patients.
The trial collaborates with two ongoing exploratory biomarker studies collecting and analyzing potential biomarkers in urothelial bladder cancer. The hope is to provide biomarkers for prognosis and treatment response which is essential to ensure bladder cancer patients individualized treatment in the future, like those with breast and prostate cancer.
Inclusion: Oral and written consent; Histologically confirmed MIBC with urothelial component; Male or female participants ≥ 18 years old; Deemed not to benefit from curative treatment at a multidisciplinary tumour conference (MDT) or having declined curative treatment of their own accord.
Exclusion: Previous pelvic RT with significant overlap; Clinical Fragility Scale score ≥8; Visceral or bone metastases on CT scan; Multiple (>3) lymph node metastases with a measurement of >2 cm on CT scan; Planed for systemic treatment at the time of inclusion; Local RT to the bladder indicated for the palliation of symptoms at the time of inclusion.